Aytu Biopharma (AYTU) Corporate presentation summary

Mission and therapeutic focus

• Focuses on improving patient lives, especially those with complex CNS conditions such as major depressive disorder (MDD) and ADHD.

• Portfolio includes novel therapeutics for MDD and ADHD, with additional pediatric products.

Product portfolio and innovation

• Features differentiated, patent-protected prescription brands, including EXXUA for MDD and Adzenys XR-ODT and Cotempla XR-ODT for ADHD.

• EXXUA is a first-in-class 5HT1A agonist for MDD, offering efficacy without common antidepressant side effects.

• ADHD and pediatric brands include unique formulations and first-to-market products.

Market opportunity and competitive positioning

• US MDD market exceeds $22B, with high unmet needs due to side effects and ineffectiveness of current therapies.

• EXXUA addresses key issues like sexual dysfunction and weight gain, differentiating it from SSRIs and SNRIs.

• ADHD and pediatric products have strong clinical data and unique FDA approvals.